Literature DB >> 12661775

Focus on paroxetine.

Ben Green1.   

Abstract

This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects. Overall, paroxetine is a well-tolerated and safe first-line SSRI antidepressant with anxiolytic qualities. It has been found useful in depression, anxiety and other conditions such as obsessive compulsive disorder and post-traumatic stress disorder. The antidepressant has some advantages over earlier tricyclic medication in terms of a lack of cardiovascular side-effects and relative safety in overdose. Cessation of use, however, is associated with withdrawal or discontinuation symptoms and patients should be counselled as to how these might be avoided. A 3- or 4-week graded withdrawal regimen, perhaps with concomitant fluoxetine to cover serotonergic discontinuation symptoms, may be advisable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661775     DOI: 10.1185/030079902125001353

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome.

Authors:  Akio Himei; Takehiko Okamura
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients.

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2003-09-02       Impact factor: 8.262

3.  Quality of life and use of health care resources among patients with chronic depression.

Authors:  Renata Villoro; María Merino; Alvaro Hidalgo-Vega
Journal:  Patient Relat Outcome Meas       Date:  2016-09-26

Review 4.  Paroxetine-Overview of the Molecular Mechanisms of Action.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Łukasz Fijałkowski; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

5.  Multigram-scale flow synthesis of the chiral key intermediate of (-)-paroxetine enabled by solvent-free heterogeneous organocatalysis.

Authors:  Sándor B Ötvös; Miquel A Pericàs; C Oliver Kappe
Journal:  Chem Sci       Date:  2019-10-18       Impact factor: 9.825

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.